Teva Pharmaceuticals has filed a petition with the U.S. Supreme Court asking for a review of a lower court’s ruling that invalidated key patents for the company’s multiple sclerosis drug Copaxone. A Teva spokeswoman confirmed the filing, but said the company would have no additional comment on the matter. Copaxone, which generated about $3.8 billion in sales for Teva (NYSE: TEVA) last year, is scheduled to lose patent protect in May.
Help employers find you! Check out all the jobs and post your resume.
